x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

science life sciences

All Episodes

1:39

Pharmaceutical Executive Daily: FDA Approves First...

Pharmaceutical Executive ·

2026/02/05

In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical protocols should be treated as product launch blueprints, and Veradermics completes an upsized $256 million IPO.

en-us

1:46

Pharmaceutical Executive Daily: Susan G. Komen...

Pharmaceutical Executive ·

2026/02/04

In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders explore how pharma can tap into emerging talent hubs, and Novartis’ Q4 results highlight mounting pressure from its upcoming patent cliff.

en-us

1:52

Pharmaceutical Executive Daily: SanegeneBio's $1.5...

Pharmaceutical Executive ·

2026/02/03

In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous indication of Saphnelo, and SanegeneBio enters a $1 billion global licensing agreement with Genentech focused on RNAi development.

en-us

1:40

Pharmaceutical Executive Daily: FDA Reveals PreCheck...

Pharmaceutical Executive ·

2026/02/02

In today’s Pharmaceutical Executive Daily, the FDA introduces a PreCheck pilot program aimed at strengthening domestic manufacturing oversight, an ACIP member alleges FDA leadership halted a decision related to COVID-19 vaccines, and Eli Lilly announces plans for a $3 billion manufacturing facility in Pennsylvania.

en-us

1:35

Pharmaceutical Executive Daily: Public Citizen Sues...

Pharmaceutical Executive ·

2026/01/30

In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving Pfizer and Eli Lilly, HHS releases new guidance aimed at lowering prescription drug costs through direct-to-consumer programs, and AstraZeneca enters a multibillion-dollar collaboration with CSPC Pharmaceutical Group.

en-us

1:40

Pharmaceutical Executive Daily: The Disconnect...

Pharmaceutical Executive ·

2026/01/29

In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still struggle to deliver truly integrated healthcare solutions, questions emerge around U.S. funding tied to global vaccine policy shifts, and the FDA approves a new treatment option for adults with presbyopia.

en-us

1:51

Pharmaceutical Executive Daily: Eli Lilly Enters $1...

Pharmaceutical Executive ·

2026/01/28

In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardiometabolic therapies, Eli Lilly enters a billion-dollar research partnership targeting hearing loss, and industry leaders examine what it takes to bring breakthrough rare disease products to patients.

en-us

1:58

Pharmaceutical Executive Daily: Roche Reports...

Pharmaceutical Executive ·

2026/01/27

In today’s pharmaceutical executive daily, Roche reports positive Phase II results for a dual GLP-1/GIP receptor agonist, procurement leaders reassess compliance risks tied to unmanaged tail spend, and Boehringer Ingelheim enters a $1 billion collaboration with Simcere to advance bispecific antibody research.

en-us

1:57

Pharmaceutical Executive Daily: Mirum Pharmaceuticals...

Pharmaceutical Executive ·

2026/01/26

In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million acquisition, industry experts examine why data visualization remains a weak point in biotech decision-making, and pediatricians weigh in on evolving vaccine guidance amid ongoing debate.

en-us

1:51

Pharmaceutical Executive Daily: Tariff Uncertainty...

Pharmaceutical Executive ·

2026/01/23

In today’s Pharmaceutical Executive Daily, tariff uncertainty triggers a short-term surge in pharmaceutical manufacturing activity, workforce burnout threatens the stability of the blood supply, and industry leaders assess whether artificial intelligence in pharma is reaching a critical inflection point.

en-us

1:59

Pharmaceutical Executive Daily: United States' Set to...

Pharmaceutical Executive ·

2026/01/22

In today’s Pharmaceutical Executive Daily, the World Health Organization finalizes the United States’ withdrawal from the global health body, Bristol Myers Squibb enters an $850 million collaboration with Janux Therapeutics to advance tumor-activated cancer therapies, and industry leaders examine how real-world data is increasingly shaping patient access decisions.

en-us

1:59

Pharmaceutical Executive Daily: New Study Finds No...

Pharmaceutical Executive ·

2026/01/21

In today’s Pharmaceutical Executive Daily, a new study reignites debate over a potential link between Tylenol use and autism risk, TopGum signs a $12 million letter of intent to acquire US manufacturing operations, and industry leaders weigh whether to build or buy AI capabilities amid accelerating digital transformation.

en-us

1:47

Pharmaceutical Executive Daily: GSK's $2 Billion...

Pharmaceutical Executive ·

2026/01/20

In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of RAPT Therapeutics, Atkins launches a new partnership to better understand consumer mindsets around GLP-1 use, and Shionogi agrees to acquire Pfizer’s remaining stake in ViiV Healthcare.

en-us

2:00

Pharmaceutical Executive Daily: Henlius' Exclusive...

Pharmaceutical Executive ·

2026/01/19

In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class anti-IL-1RAP antibody, a new report highlights drugmakers raising list prices amid pricing agreements with the Trump administration, and Novartis urges governments to address mounting global trade policy challenges impacting the biopharmaceutical industry.

en-us

1:46

Pharmaceutical Executive Daily: President Trump's...

Pharmaceutical Executive ·

2026/01/16

In today’s Pharmaceutical Executive Daily, Johnson & Johnson announces plans for a second $2 billion manufacturing facility in North Carolina, President Trump calls on Congress to enact a sweeping healthcare reform package, and new analysis highlights how frontline biopharma sales professionals are rethinking compensation and financial planning strategies.

en-us

1:42

Pharmaceutical Executive Daily: Continued Coverage of...

Pharmaceutical Executive ·

2026/01/15

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Genmab outlining a disciplined strategy focused on sustained growth over the next decade, AbbVie highlighting continued pipeline advancements as it prepares for future revenue transitions, and Novavax detailing its shift toward a partnership-driven operating model.

en-us

1:50

Pharmaceutical Executive Daily: 2026 J.P. Morgan...

Pharmaceutical Executive ·

2026/01/14

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Biogen outlining how a more focused company is emerging following years of transformation, Merck detailing its strategy to de-risk long-term funding and pipeline investment, and Eli Lilly reinforcing its confidence in sustaining GLP-1-driven growth.

en-us

1:49

Pharmaceutical Executive Daily: Johnson & Johnson...

Pharmaceutical Executive ·

2026/01/12

In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while continuing its $55 billion U.S. investment plan, Bristol Myers Squibb outlines its long-term strategic focus at JPMorgan 2026, and Pfizer details its pivot from COVID-era products toward pipeline execution.

en-us

1:48

Pharmaceutical Executive Daily: FDA Limits...

Pharmaceutical Executive ·

2026/01/08

In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry leaders examine how humans and AI can jointly create value in pharma, and Eli Lilly enters a billion-dollar agreement to acquire Ventyx Biosciences.

en-us

1:36

Pharmaceutical Executive Daily: Amgen Acquires Dark...

Pharmaceutical Executive ·

2026/01/07

en-us

282 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter